QURE - NASDAQ

uniQure N.V.

uniQure N.V.

QUREยทNASDAQ

$30.41

+1.8%
HealthcareBiotechnology

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$1.92B
EPS-3.4600
P/E Ratio-8.79
Earnings Date08/04/2026
uniQure N.V.

uniQure N.V. Fair Value Envelope

QURE ยท NASDAQ

Our analysis suggests that QURE has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $30.41, this represents a potential HIDDEN relative to our calculated worth for uniQure N.V..

HIDDEN
Intrinsic Value
Current Price: $30.41

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$1.5B
+ Cash & Equivalents$80.2M
Firm Value-$1.4B
- Debt$536.6M
Equity Value-$1.9B
/ Shares Outstanding62,529,400B
DCF Value-$31
OVERVALUED BY 202%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$185.7M
-$193.9M
-$202.3M
-$211.2M
-$220.4M
-$230.0M
-$240.1M
-$250.6M
-$261.5M
-$273.0M
Maintenance CapEx
-$91.6K
-$95.6K
-$99.8K
-$104.2K
-$108.7K
-$113.5K
-$118.4K
-$123.6K
-$129.0K
-$134.7K
Owner Earnings
-$185.8M
-$194.0M
-$202.4M
-$211.3M
-$220.5M
-$230.1M
-$240.2M
-$250.7M
-$261.7M
-$273.1M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$172.1M
-$166.3M
-$160.7M
-$155.3M
-$150.1M
-$145.0M
-$140.2M
-$135.4M
-$130.9M
-$126.5M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your QURE research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.